| ||
| Mepolizumab for severe eosinophilic asthma (DREAM): a - The Lancet The primary outcome was the rate of clinically significant asthma exacerbations, which were defined as validated episodes of acute asthma requiring treatment ... www.thelancet.com/journals/lancet/article/PIIS0140.../abstract |
Tip: Use quotes ("like this") around a set of words in your query to match them exactly. Learn more.
Delete this alert.
Create another alert.
Manage your alerts.
No comments:
Post a Comment